Tikvah Pharmaceuticals

Tikvah Pharmaceuticals was a clinical-stage biopharmaceutical company focused on the development of therapies for Central Nervous System (CNS) disorders. The company's primary focus was on improving the delivery and efficacy of existing treatments for Parkinson's disease, specifically through its lead candidates T-2000 and T-2007. These programs utilized optimized formulations of carbidopa, levodopa, and entacapone to address motor fluctuations and "off" time in patients. Headquartered in Atlanta, Georgia, the company also explored treatments for ADHD and sleep disorders. Tikvah aimed to leverage known compounds with established safety profiles to reduce development risk and time to market. The company appears to have ceased active operations in the early 2010s following clinical and legal challenges.